MAYNE Pharma this week
confirmed that sales of its Doryx
(delayed release Doxycycline)
product have been impacted by the
“unprecedented strength of the
Australian dollar” as well as the
repositioning of the product in the
lead-up to the introduction of new
dosage forms in the USA.
The company says it’s confident
that FDA approval for the new
formulations will be received
shortly, and possibly before 30 Jun.
In the meantime it’s conducted a
review of operations at its Salisbury
production site, and identified a
number of redundant roles and
“other cost savings that will
eliminate non-value added activity”
with redundancy costs of $1.1m
and onoing savings of $2.9m a year.
Mayne also said the European
approval process for its Subacap
(itraconazole) is still “on track”.The above article was sent to subscribers in Pharmacy Daily's issue from 17 Jun 11 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Jun 11